HDAC9 and metabolic dysfunction-associated steatotic liver disease: Resveratrol has not had a therapeutic benefit in overweight and obese men with established NAFLD (250), and the role of HDAC activation as a protective or therapeutic intervention for NAFLD remains unclear in humans.